Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population

Luchner, Andreas; Burnett, John C.; Jougasaki, Michihisa; Hense, Hans Werner; Heid, Iris M.; Muders, Frank; Riegger, G. A. J.; Schunkert, Heribert

doi:10.1097/00004872-200018080-00018

Cited by 154 publications

(98 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study with 32 patients, we found NT-proBNP to be a reliable marker to make this differentiation with a sensitivity of 100% and a specificity of 83%. This is comparable to the literature for diagnosis of cardiac dysfunction in the general population (McDonagh et al, 1998;Luchner et al, 2000) or in patients suspected to have heart failure (Cowie et al, 1997;Maisel et al, 2002Maisel et al, , 2003. The PPV of 69% as described in our study is relatively high compared to studies in the general population with a PPV of approximately 30% (Bay et al, Figure 3 The ROC curve shows that the accuracy to differentiate between patients with and without heart disease is the best in NT-proBNP compared to ANP levels.…”

Section: Discussionsupporting

confidence: 86%

“…Large studies in the general population or in noncardiac patients showed that measuring natriuretic peptides might be an effective screening method for left-ventricular systolic dysfunction (McDonagh et al, 1998;Luchner et al, 2000;Bay et al, 2003). In patients with the suspicion of heart failure several other studies showed natriuretic peptides to be useful indicators for the detection of heart failure (Lerman et al, 1993;Davidson et al, 1996;Cowie et al, 1997;Hammerer-Lercher et al, 2001;Maisel et al, 2002Maisel et al, , 2003.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

et al. 2004

View full text Add to dashboard Cite

Carcinoid heart disease (CHD) occurs in 20 -70% of the patients with metastatic well-differentiated neuroendocrine tumours (NET). We evaluated whether natriuretic peptides (ANP or NT-proBNP) are useful in early detection of CHD. Blood samples from 32 patients with NET were compared with cardiac ultrasound follow-up. CHD was defined as thickening of the tricuspid valve in the presence of grade III -IV/IV tricuspid valve regurgitation. CHD was found in nine out of 32 patients (28%), all with symptoms of the carcinoid syndrome compared to 65% in the 23 patients without CHD (P ¼ 0.04). Median levels of NT-proBNP and 5-HIAA were significantly higher in patients with CHD (894 ng l À1 and 815 mmol 24 h À1 ) compared to those without (89 and 206 ng l À1 , Po0.001 and P ¼ 0.007). No significant differences were detected in ANP levels (P ¼ 0.11). Dilatation of the right atrium and ventricle as well as thickening of the tricuspid valve and degree of regurgitation were statistically significant correlated with NT-proBNP levels. The accuracy of NT-proBNP in the diagnosis of CHD was higher than that of ANP. A significantly better survival was observed in case of normal NT-proBNP values. In conclusion, NT-proBNP is helpful as a simple marker in the diagnosis of CHD. Survival is better in patients with normal levels of NT-proBNP.

show abstract

Section: Discussionsupporting

confidence: 86%

mentioning

confidence: 99%

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

et al. 2004

View full text Add to dashboard Cite

show abstract

“…This finding is supported by population-based studies, where subjects with LVH or left ventricular systolic dysfunction have been shown to have increased levels of NP, but NP have not been reported to correlate with BP or LVM. 8,9,24 Furthermore, plasma BNP levels are not increased in cyclists with significant LVH, 25 and we have shown that most of the patients with non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the a-tropomyosin gene and marked LVH have normal plasma NT-proBNP levels. 26 Although LA size is an independent predictor of cardiovascular mortality and morbidity, 27,28 the mechanism of the LA enlargement remains poorly elucidated.…”

Section: Discussionmentioning

confidence: 68%

“…5 Elevated levels of natriuretic peptides (NPs) in hypertension often have been attributed to the presence of LVH. 6,7 Although NP are not useful for community screening for LVH, 8,9 they might be useful for the early detection of LVH in patients with essential hypertension. 7 Although the association between NP and LVH has been demonstrated in patients with severe hypertension and high prevalence of LVH, 6,7 the applicability of this data to patients with mild hypertension is not known.…”

Section: Introductionmentioning

confidence: 99%

N-terminal pro-atrial natriuretic peptide reflects cardiac remodelling in stage 1 hypertension

et al. 2011

View full text Add to dashboard Cite

Early detection of left ventricular hypertrophy (LVH) is beneficial, since treatment-induced regression of LVH has been unequivocally associated with a better prognosis. Our aim was to study the relation of cardiac remodelling and natriuretic peptides (NPs) in stage 1 hypertension. We studied 175 (46 ± 7 years, 87 women and 88 men) apparently healthy middle-aged that had never been treated for hypertension. Left ventricular and atrial parameters were determined by magnetic resonance imaging. Systolic blood pressure (BP) correlated with left ventricular mass index (LVMI) (r ¼ 0.23, Po0.01) and ventricular septum thickness index (IVSI) (r ¼ 0.29, Po0.001). N-terminal pro-B-type NP (NT-proBNP) or N-terminal pro-atrial NP (NT-proANP) did not correlate with BP, LVMI or IVSI. NT-proANP correlated with left atrial area index (LAAI) (r ¼ 0.38, Po0.001), and subjects with LVH had higher LAAI than subjects with normal left ventricular geometry and no LVH (11.2±0.3 vs 10.0 ± 0.2 cm 2 m -2 , Po0.001). In conclusion, measurement of NT-proBNP or NT-proANP does not appear to discriminate LVH in middle-aged, never treated and apparently healthy hypertensives. NT-proANP, but not NT-proBNP, reflects early cardiac remodelling in hypertensive heart disease.

show abstract

“…Recently, pro-BNP have received major attention as cardiovascular marker because this peptide is secreted in case of volume overload and increased ventricular wall tension (19)(20)(21). In addition, pro-BNP was identified as a discerning marker of LVH and/or early LVD.…”

Section: Discussionmentioning

confidence: 99%

Relationship between N-Terminal Pro B-Type Natriuretic Peptide and Body Mass Index

Sahin¹,

Kutlutürk²,

Taşlıyurt³

et al. 2013

Turk J Bioch

View full text Add to dashboard Cite

AbstractÖzet Objective: N-terminal pro B-type natriuretic peptide (NT-pro BNP) is secreted from the cardiac ventricles in response to volume expansion. The effect of obesity on natriuretic peptide has yet to be fully elucidated. We aimed to compare the NT-pro BNP levels in obese and in healthy individuals with normal body mass index. Method: Forty-two obese patients (37 women, 5 men; body mass index ≥ 30) and thirty-five normal body mass index individuals (27 women, 8 men; body mass index ≤ 25) were analyzed regarding NT-pro BNP. Results: The serum levels of NT-pro BNP was significantly higher in obese patients than normal body mass index individuals (p=0,027). No correlation was found between body mass index and NT-pro BNP. Statistically significant difference was found between systolic and diastolic blood pressures in both groups (p<0.001 and p<0.001; respectively) Conclusion: We found that NT-pro BNP was higher in obese than control groups. Elevated NT-pro BNP in obese patients may be explained by changes in the heart structure that hypertension leads.Amaç: N-terminal pro B-tip natriüretik peptid (NT-pro BNP) hacim genişlemesinde yanıt olarak kardiyak ventriküllerden salgılanır. Natriüretik peptid üzerine obezitenin etkisi henüz tam olarak aydınlatılmış değildir. Bu çalışmada normal kilolu ve obez bireylerde NT-pro BNP düzeylerinin karşılaştırılması amaçlandı. Yöntem: Çalışmaya kırkiki obez hasta (37 kadın, 5 erkek; vücut kitle indeksi ≥ 30) ve normal kilolu otuzbeş kişi (27 kadın, 8 erkek; vücut kitle indeksi ≤ 25) kontrol grubu olarak alındı. Hasta ve kontrol grubunun NT-pro BNP düzeyleri karşılaştırıldı. Bulgular: NT-pro BNP düzeyleri obez hastalarda kontrol grubuna göre anlamlı olarak yüksek bulundu (p=0.027). Vücut kitle indeksi ile NT-pro BNP arasında korelasyon yoktu. Obez hastalarda sistolik ve diyastolik kan basınçları istatistiksel olarak yüksekti (sırasıyla; p <0.001 ve p <0.001). Sonuç: Obezlerde kontrol grubuna göre NT-pro BNP düzeyleri daha yüksek olduğu bulundu. Obez hastalardaki yüksek NT-pro BNP hipertansiyonun yol açtığı kalp yapısındaki değişiklikler ile açıklanabilir.

show abstract

Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population

Cited by 154 publications

References 25 publications

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

N-terminal pro-atrial natriuretic peptide reflects cardiac remodelling in stage 1 hypertension

Relationship between N-Terminal Pro B-Type Natriuretic Peptide and Body Mass Index

Contact Info

Product

Resources

About